Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

Ketamine is often viewed more as a party drug than a medicine. One Columbia clinic is using the drug to help patients with ...

H.C. Wainwright tells investors in a research note that Compass Pathways (CMPS) is one of the most compelling stories in neuropsychiatry, and ...

Ketamine advertisements are popping up all around us. With few regulations in place, might we be witnessing another opioid ...

The government is preparing to fund the use of MDMA and psylocibin, otherwise known as ecstasy and magic mushrooms, as a ...

The company announced on 18 February that the trial did not meet its primary endpoint measured by a depression rating scale, ...

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) revealed the topline data from the Phase 2b study of SPN-820 in adults with ...

Psychedelics have been recreational substances for decades. Now, they're entering the mainstream of psychiatric treatment.

Faster-acting drugs have long been sought to protect people with severe depression who may be at risk of self-harm or suicide ...

Ketamine, a non-competitive N-methyl-D-aspartate receptor antagonist, has emerged as an effective therapeutic agent for the management of treatment-resistant depression. Repeated treatments with ...

IntroductionMajor depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing ...